Bavarian Nordic
Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial. Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or placebo (n = 3).
Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial. Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or placebo (n = 3). Recruitment into the trial will be performed in a staggered approach. In each cohort, participants will be randomized to receive either MVA-BN-EBV or placebo. The trial will start with a sentinel cohort of 2 participants, 1 receiving the MVA-BN-EBV vaccine and the other receiving the placebo.
Inclusion Criteria: 1. Age ≥18 and ≤30 years at screening 2. Informed consent form (ICF) signed and dated by the participant after reading the form and being advised of the risks and benefits of the trial in a language understood by the participant and before performance of any trial-specific procedures 3. General good health, without any clinically relevant medical illness, physical exam findings, or laboratory abnormalities, as determined by the PI 4. Body mass index (BMI) ≥18.5 and ≤35.0 • BMI formula for kilograms and meters (round to 1 decimal place): BMI = (body weight in kilograms)…
MVA-BN-EBV
Placebo
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.